Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K, SPECIAL MEETING RESULTS - LIFE SCIENCES RESEARCH INC | form8kspecialmeeting.htm |
Exhibit
99.1
|
PRESS
RELEASE
|
LIFE
SCIENCES RESEARCH, INC.
|
|
(NYSE
Arca: LSR)
|
|
|
PO
Box 2360
|
|
|
Mettlers
Road
|
|
|
East
Millstone, NJ 08875-2360
|
|
|
For
Further Information:
|
|
|
Richard
Michaelson
|
|
|
Phone:
US (732) 649-9961
|
|
|
Email:
LifeSciencesResearch@LSRinc.net
|
November
23, 2009
Life
Sciences Research, Inc.’s Stockholders Approved Going Private
Transaction
East
Millstone, New Jersey, November 23, 2009 – Life Sciences Research, Inc. (NYSE
Arca: LSR) announced today that, at a special meeting of its stockholders held
today, its stockholders voted to approve the merger of Lion Merger Corp. with
and into LSR pursuant to the Agreement and Plan of Merger, dated as of July 8,
2009, among LSR, Lion Holdings, Inc., and Lion Merger Corp., as amended by
Amendment No. 1 to Agreement and Plan of Merger, dated as of October 20, 2009,
among LSR, Lion Holdings, Inc., and Lion Merger Corp.
The
transaction is expected to be consummated on or about November 24, 2009, subject
to the satisfaction of customary closing conditions. At the effective
time of the merger, the separate corporate existence of Lion Merger Corp. will
cease, and LSR will survive as a wholly owned subsidiary of Lion Holdings,
Inc. Pursuant to the Agreement and Plan of Merger, as amended, at the
effective time of the merger, each outstanding share of the voting common stock,
par value $0.01 per share, of LSR (other than shares owned by Lion Holdings,
Inc., Lion Merger Corp. or any other direct or indirect wholly owned subsidiary
of Lion Holdings, Inc. and LSR, and in each case not held on behalf of third
parties) will be cancelled and converted into the right to receive $8.50 per
share in cash, without interest and less any applicable withholding
taxes.
About
Life Sciences Research
Life
Sciences Research, Inc. is a global contract research organization providing
product development services to the pharmaceutical, agrochemical and
biotechnology industries. LSR brings leading technology and
capability to support its clients in non-clinical safety testing of new
compounds in early stage development and assessment. The purpose of
this work is to identify risks to humans, animals or the environment resulting
from the use or manufacture of a wide range of chemicals which are essential
components of LSR’s clients’ products. LSR’s services are designed to
meet the regulatory requirements of governments around the world. LSR
operates research facilities in the United States (the Princeton Research
Center, New Jersey) and the United Kingdom (Huntingdon and Eye,
England).
Forward
Looking Statements
This
announcement contains statements that may be forward-looking as defined by the
Private Securities Litigation Reform Act of 1995. These statements
are based largely on LSR’s expectations and are subject to a number of risks and
uncertainties, certain of which are beyond LSR’s control, including without
limitation the ability to satisfy the conditions to closing set forth in the
Agreement and Plan of Merger, as amended, and other risks and uncertainties as
more fully described in LSR’s SEC filings, including its Form 10-K for the
fiscal year ended December 31, 2008, as filed with the U.S. Securities and
Exchange Commission.